Walter H. Moos, PhD

Walter Moos has been a Managing Member of Pandect Catalyst since 2023 and a Managing Director of Pandect Bioventures, which he co-founded in 2018. Starting in 2016, he was an advisor, CEO, and then Chairman emeritus at SP Innovation, where he led development of the group's innovation ecosystem. Moos was President of SRI Biosciences until 2016 after more than a decade at the independent nonprofit SRI International (Stanford Research Institute). He also managed corporate Information Technology Services at SRI. In parallel, Moos has been an adjunct Professor of Pharmaceutical Chemistry at UCSF since 1992. Earlier he was Chairman/CEO of MitoKor (Micrologics/Migenix) and a VP at Chiron (Novartis) and Warner-Lambert/Parke-Davis (Pfizer).

He and his teams have made contributions to all R&D phases, from early-stage research on chemical and biological therapeutics and diagnostics to marketed pharmaceutical products. They have done this with the support of VCs, foundations, government agencies, big pharma, and many others.

Moos has served on more than 20 business and scientific boards, public and private, non-profit and for-profit, including Alnis, Amunix (Sanofi), Anterion, Aprinoia, Axiom (Sequenom), the Biotechnology Industry (now Innovation) Organization (BIO), Circle, the Critical Path Institute, Global Blood (Pfizer), Keystone Symposia, Mimotopes (Fisher/Thermo), MitoKor (Micrologics/Migenix), Oncologic (Aduro/Chinook/Novartis), Onyx (Amgen), Organos, Rigel, SP Innovation, Valitor, and the Virginia University Research Partnership.

He has advised companies on several continents and served as a committee member for academic, government, and investor groups, including the U.S. National Academy of Sciences. He has co-founded several scientific journals, authored or edited 7 books, and altogether has more than 200 patents and publications. Moos has held faculty positions at several major universities and received PhD and AB degrees in chemistry from UC Berkeley and Harvard, respectively.

‍